Financial Reports

Raysearch Laboratories AB (PUBL) Interim Report January 1 – September 30, 2013


  • Net sales for the period amounted to SEK 114.4 M (105.2)
  • A loss after tax of SEK 25.9 M (loss: 5.5) was reported, as well as a loss per share of SEK 0.76 (loss: 0.16)
  • The operating loss was SEK 26.1 M (loss: 3.7)
  • Cash flow amounted to a negative SEK 28.0 M (pos: 14.9)
  • First orders for RayStation® from Spain and France
  • Collaboration agreement signed with IBA
  • Partnership agreement with Brainlab announced
  • RayStation® 4.0 released
  • RayStation® approved for sales in China and the first Chinese order received
  • First patient in Oceania treated with RayStation®
  • US proton center selected RayStation®


  • First Scandinavian order for RayStation®
  • Distribution agreement signed with Hitachi Medical Corporation
  • First patient in China treated with RayStation®

”Sales rose during the first nine months of the year as a result of increased deliveries of RayStation® and growing partner sales. However, the result for the period fell due to investments in the build-up of infrastructure for sales, marketing and support of RayStation®, higher development costs and higher legal fees related to the patent dispute in the US.”, says Johan Löf, President of RaySearch.

”Several strategic milestones have been reached to date in 2013 and RayStation® is evolving at a fast pace. While a great deal of work remains ahead for expanding our sales and service organization, interest in the system is rising continuously and we are involved in an increasing number of business discussions throughout the world. It is difficult to predict how rapidly the interest will translate into orders and deliveries, but the prospects are favorable for a very strong end of 2013”, concludes Johan Löf.     

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,300 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit

Johan Löf, President
Tel: +46 (0)8-545 061 30